May 1st 2024
C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Daratumumab Triplets Approved by FDA for Relapsed Myeloma
November 22nd 2016Daratumumab (Darzalex) has received FDA approval in combination with lenalidomide (Revlimid) and dexamethasone or bortezomib (Velcade) and dexamethasone for patients with relapsed multiple myeloma following at least 1 prior therapy.
Read More
Anderson Suggests Novel Treatments for Relapsed/Refractory Multiple Myeloma
October 21st 2016The current treatment landscape for relapsed and refractory multiple myeloma is so promising, oncologists should not hesitate to consider integrating novel therapies into multiple myeloma management, Kenneth C. Anderson, MD, said.
Read More
Kumar Speaks on Role of MRD Testing in Myeloma
October 10th 2016<em>Targeted Oncology</em> speaks with Shaji Kumar, MD, to understand the roles that the new criteria for response and minimal residual disease (MRD) assessment in multiple myeloma and what role MRD testing will play going forward in multiple myeloma.<br />
Read More
FDA Grants Priority Review to Daratumumab Combination for Relapsed Myeloma
October 10th 2016The FDA has granted a priority review designation to daratumumab (Darzalex) in combination with lenalidomide (Revlimid) and dexamethasone or bortezomib (Velcade) and dexamethasone for patients with relapsed multiple myeloma following at least 1 prior therapy.
Read More
CHMP Recommends Conditional Approval for Ixazomib Combo in Myeloma
September 19th 2016Based on findings from the phase III TOURMALINE-MM1 study, the Committee for Medicinal Products for Human Use (CHMP) has recommended a conditional approval for ixazomib (Ninlaro) in combination with lenalidomide and dexamethasone as a treatment for patients with multiple myeloma who have received at least 1 prior therapy.
Read More
Insight into Drug Therapy and Stem Cell Transplant Options for Relapsed Myeloma Patients
August 26th 2016<p>A set of guidelines for treating patients with relapsed and refractory multiple myeloma published by the International Myeloma Working Group may not aid researchers in identifying ideal treatment paths for those with relapsed and refractory disease until more genomic data has been gathered.</p>
Read More
Redefining Multiple Myeloma Diagnosis and Management
August 24th 2016This article reviews some of the concepts surrounding the diagnosis of multiple myeloma are still evolving, and are thus shaping how we see and manage multiple myeloma - hopefully moving slowly but surely toward its elusive cure.
Read More
Daratumumab Receives Breakthrough Designation for Use in Combo Treatments for Myeloma
July 27th 2016Daratumumab (Darzalex) has been granted a breakthrough therapy designation by the FDA for use in the treatment of patients with multiple myeloma following at least 1 prior therapy. The CD38-targeted antibody is accepted for use in combination with lenalidomide/dexamethasone or bortezomib/dexamethasone, according to Janssen, which is developing daratumumab with Genmab.
Read More
Daratumumab Shown to Double Response in Refractory Multiple Myeloma
June 7th 2016Daratumumab (Darzalex), when added to the standard two-drug regimen of bortezomib and dexamethasone, reduced the risk of progression or death by 61% compared with the standard regimen alone for patients with recurrent or refractory multiple myeloma.
Read More
KPd Triple-Combination Shows Potential in Refractory Multiple Myeloma
June 7th 2016A regimen consisting of carfilzomib (Kyprolis), pomalidomide (Pomalyst), and dexamethasone (KPd) merits further investigation for the treatment of patients with multiple myeloma whose disease progresses while on lenalidomide (Revlimid) in the earlier stages of disease.
Read More
Isatuximab Demonstrates Activity as Single-Agent in Multiple Myeloma
June 7th 2016The anti-CD38 monoclonal antibody isatuximab (SAR650984) showed promising signs of activity as a single-agent for patients with heavily pretreated relapsed/refractory multiple myeloma, according to updated findings from a phase II study presented at the 2016 ASCO Annual Meeting.
Read More
Frontline Myeloma Therapies Undergoing Dramatic Transformation
May 5th 2016The high level of efficacy observed with the combination of bortezomib, lenalidomide, and dexamethasone in the phase III SWOG S0777 study significantly changed the frontline treatment paradigm for patients with multiple myeloma.
Read More